Kyntra Bio (LTS:0IL8) Beta: 0.7371 (As of Jun. 25, 2026)


LTS:0IL8 Kyntra Bio Inc LTS:0IL8
52 GF Score
Price $6.86
GF Value $5.68
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Kyntra Bio Beta?

Kyntra Bio LTS:0IL8 52 Beta is 0.7371 as of Jun. 25, 2026. GuruFocus rates LTS:0IL8 with a GF Score™ of 52/100 and a GF Value™ of $5.68 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Kyntra Bio's Beta is 0.7371.


Kyntra Bio  (LTS:0IL8) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Kyntra Bio Beta Related Terms


Kyntra Bio Beta Historical Data

* Premium members only.

The historical data trend for Kyntra Bio's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyntra Bio Beta Chart

Kyntra Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 1.45 1.11 1.95

Kyntra Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.03 1.35 1.57 1.95 0.56

LTS:0IL8 vs SER, SNSE, PVCT: Beta Comparison

For the Biotechnology subindustry, Kyntra Bio's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyntra Bio Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyntra Bio's Beta distribution charts can be found below:

* The bar in red indicates where Kyntra Bio's Beta falls into.


LTS:0IL8
52GF Score
Kyntra Bio Inc LTS:0IL8
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyntra Bio Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.7371 mean?
Kyntra Bio (LTS:0IL8) has a Beta of 0.7371 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Kyntra Bio and its competitors.
Is Kyntra Bio's Beta too high?
Kyntra Bio's current Beta is 0.7371. Overall, Kyntra Bio has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's Beta compare to SER and SNSE?
Kyntra Bio's Beta of 0.7371 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Kyntra Bio and its competitors. Kyntra Bio's current Beta is 0.7371. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (LTS:0IL8) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.68, compared to a current price of $6.86 — trading 20.7% above its estimated fair value. The current Beta is 0.7371. Kyntra Bio's overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Kyntra Bio (LTS:0IL8), the current Beta is 0.7371 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of $6.86 is trading 20.7% above its estimated GF Value™ of $5.68. GuruFocus considers Kyntra Bio to be Modestly Overvalued.

Key valuation signals for LTS:0IL8:

  • Beta: 0.7371
  • GF Value™: $5.68 vs. price of $6.86 (20.7% above fair value)
  • GF Score™: 52/100 with 8 warning signs

No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyntra Bio Business Description

Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
52GF Score

Get the complete analysis for LTS:0IL8

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.86
Price
$5.68
GF Value